A retrospective study sought to determine the risk of adverse events with the use of TKIs and mTOR inhibitors for renal cell carcinoma in patients with renal impairment or ESRD.
Microstimulation model identifies most cost-effective of 6 immune checkpoint inhibitor strategies for the first-line treatment of advanced renal cell carcinoma.
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
Investigators concluded that there is minimal to no clinical value in surveillance for pulmonary recurrence after T1a RCC resection.
Researchers found preoperative blood glucose levels were associated with hospital length of stay for patients undergoing laparoscopic nephrectomy for RCC.
The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other VHL-associated tumors.
Researchers concluded that pembrolizumab plus axitinib may be the most effective first-line immunotherapy for mRCC
Decisions of how to proceed when positive surgical margins are found after partial nephrectomy are left to the discretion of the surgeon.
Researchers applied a 27-gene classifier proven effective with breast, lung, and bladder cancers to predict efficacy of ICI therapy in patients with RCC.
Compared with men, women had significant 18% lower odds of undertreatment and 27% higher odds of overtreatment of kidney cancer, according to a study.
